Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice

Frontiers in Bioscience

Volumn 13, Issue 18, 2008, Pages 6850-6858

  Yazbeck, Roger ^a,b   Howarth, Gordon S ^a,b,c   Geier, Mark S ^b,c   Demuth, Hans Ulrich ^d   Abbott, Catherine A ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d PROBIODRUG AG   (Germany)

Author keywords

Dextran sulfate sodium; Dipeptidyl peptidase inhibitor; Glucagon like peptide 2; Inflammatory bowel disease; Mouse model

Indexed keywords

ANIMALIA; MUS;

DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ANIMAL; ARTICLE; BLOOD; COLITIS; DISEASE MODEL; DRUG ANTAGONISM; ENTERITIS; ENZYMOLOGY; KINETICS; METABOLISM; MOUSE;

ANIMALS; ANTIGENS, CD26; COLITIS; DIPEPTIDYL PEPTIDASES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; INFLAMMATORY BOWEL DISEASES; KINETICS; MICE;

EID: 52049083870     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3193     Document Type: Article

References (54)

1. Rutgeerts, P.: A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol, 17 Suppl, S176-85 (2002) (Pubitemid 34539307)
2. Farrell, R. J. & M. A. Peppercorn: Ulcerative colitis. Lancet, 359, 331-40 (2002) (Pubitemid 34119301)
3. Hendrickson, B. A., R. Gokhale & J. H. Cho: Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev, 15, 79-94 (2002) (Pubitemid 34052583)
4. Drucker, D. J.: Gut adaptation and the glucagon-like peptides. Gut, 50, 428-35 (2002) (Pubitemid 34161064)
5. Drucker, D. J.: Glucagon-like peptide 2. J Clin Endocrinol Metab, 86, 1759-64 (2001) (Pubitemid 32374934)
6. Orskov, C., B. Hartmann, S. S. Poulsen, J. Thulesen, K. J. Hare & J. J. Holst: GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept, 124, 105-12 (2005) (Pubitemid 39488347)
7. Drucker, D. J., P. Erlich, S. L. Asa & P. L. Brubaker: Induction of intestinal epithelial proliferation by glucagonlike peptide 2. Proc Natl Acad Sci U S A, 93, 7911-6 (1996) (Pubitemid 26277138)
8. Brubaker, P. L., A. Izzo, M. Hill & D. J. Drucker: Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol, 272, E1050-8 (1997)
9. Alavi, K., M. Z. Schwartz, J. P. Palazzo & R. Prasad: Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg, 35, 847-51 (2000) (Pubitemid 30346176)
10. Boushey, R. P., B. Yusta & D. J. Drucker: Glucagonlike peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res, 61, 687-93 (2001) (Pubitemid 32128634)
11. Boushey, R. P., B. Yusta & D. J. Drucker: Glucagonlike peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol, 277, E937-47 (1999)
12. Hartmann, B., J. Thulesen, H. Kissow, S. Thulesen, C. Orskov, C. Ropke, S. S. Poulsen & J. J. Holst: Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology, 141, 4013-20 (2000)
13. Gorrell, M. D.: Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond), 108, 277-92 (2005) (Pubitemid 40516992)
14. Durinx, C., A. M. Lambeir, E. Bosmans, J. B. Falmagne, R. Berghmans, A. Haemers, S. Scharpe & I. De Meester: Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem, 267, 5608-13 (2000)
15. Lambeir, A. M., C. Durinx, S. Scharpe & I. De Meester: Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci, 40, 209-94 (2003) (Pubitemid 36775376)
16. Hildebrandt, M., M. Rose, J. Ruter, A. Salama, H. Monnikes & B. F. Klapp: Dipeptidyl peptidase IV (DP IV,CD26) in patients with inflammatory bowel disease. Scand J Gastroenterol, 36, 1067-72 (2001) (Pubitemid 32801692)
17. Xiao, Q., R. P. Boushey, M. Cino, D. J. Drucker & P. L. Brubaker: Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol Regul Integr Comp Physiol, 278, R1057-63 (2000) (Pubitemid 30215220)
18. Mentlein, R.: Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept, 85, 9-24 (1999) (Pubitemid 29505281)
19. Hartmann, B., M. B. Harr, P. B. Jeppesen, M. Wojdemann, C. F. Deacon, P. B. Mortensen & J. J. Holst: In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab, 85, 2884-8 (2000) (Pubitemid 32269168)
20. Thulesen, J., L. B. Knudsen, B. Hartmann, S. Hastrup, H. Kissow, P. B. Jeppesen, C. Orskov, J. J. Holst & S. S. Poulsen: The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regul Pept, 103, 9-15 (2002) (Pubitemid 34001631)
21. Abbott, C. A., D. M. Yu, E. Woollatt, G. R. Sutherland, G. W. McCaughan & M. D. Gorrell: Cloning, expressionand chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem, 267, 6140-50 (2000)
22. Ajami, K., C. A. Abbott, G. W. McCaughan & M. D. Gorrell: Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta, 1679, 18-28 (2004) (Pubitemid 38881620)
23. Bjelke, J. R., J. Christensen, P. F. Nielsen, S. Branner, A. B. Kanstrup, N. Wagtmann & H. B. Rasmussen: Dipeptidyl peptidase 8 and 9 specificity and molecular characterization compared to dipeptidyl peptidase IV. Biochem J (2006)
24. Drucker, D. J., B. Yusta, R. P. Boushey, L. DeForest & P. L. Brubaker: Human (Gly2)GLP-2 reduces the severityof colonic injury in a murine model of experimental colitis. Am J Physiol, 276, G79-91 (1999) (Pubitemid 29063603)
25. Buchman, A. L., S. Katz, M. Shnaidman & D. Jacobs: Effect of Teduglutide on Patients with Moderate-Severe Crohn's Disease after 8 Weks of THerapy: A Prospective Double-Blind, Placebo Controlled Trial. Digestive Diseases Week, Late Breaking Abstract (2006).
26. Jeppesen, P. B., E. L. Sanguinetti, A. Buchman, L. Howard, J. S. Scolapio, T. R. Ziegler, J. Gregory, K. A. Tappenden, J. Holst & P. B. Mortensen: Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagonlike peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut, 54, 1224-31 (2005) (Pubitemid 41192479)
27. Drucker, D. J., L. DeForest & P. L. Brubaker: Intestinal response to growth factors administered alone or in combination with human (Gly2)glucagon-like peptide 2. Am J Physiol, 273, G1252-62 (1997)
28. Thulesen, J., B. Hartmann, K. J. Hare, H. Kissow, C. Orskov, J. J. Holst & S. S. Poulsen: Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut, 53, 1145-50 (2004) (Pubitemid 38961969)
29. Hoffmann, T. & H. U. Demuth: Therapeutic Strategies Exploiting DP IV inhibition - Target Disease: Type 2 Diabetes. Ectopeptidases: CD13/Aminopeptidase N and CD26/Dipeptidylpeptidase IV in Medicine and Biology.259-278 (2002)
30. Pospisilik, J. A., S. G. Stafford, H. U. Demuth, R. Brownsey, W. Parkhouse, D. T. Finegood, C. H. McIntosh & R. A. Pederson: Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes, 51, 943-50 (2002) (Pubitemid 34438335)
31. Thornberry, N. A. & A. E. Weber: Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IVinhibitor for the treatment of type 2 diabetes. Curr Top Med Chem, 7, 557-68 (2007) (Pubitemid 46488280)
32. Tanaka, S., T. Murakami, N. Nonaka, T. Ohnuki, M. Yamada & T. Sugita: Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225. Immunopharmacology, 40, 21-6 (1998) (Pubitemid 28434950)
33. Tanaka, S., T. Murakami, H. Horikawa, M. Sugiura, K. Kawashima & T. Sugita: Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int J Immunopharmacol, 19, 15-24 (1997) (Pubitemid 27259665)
34. Steinbrecher, A., D. Reinhold, L. Quigley, A. Gado, N. Tresser, L. Izikson, I. Born, J. Faust, K. Neubert, R. Martin, S. Ansorge & S. Brocke: Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and upregulatesTGF-beta 1 secretion in vivo. J Immunol, 166, 2041-8 (2001) (Pubitemid 32114693)
35. Preller, V., A. Gerber, S. Wrenger, M. Togni, D. Marguet, J. Tadje, U. Lendeckel, C. Rocken, J. Faust, K. Neubert, B. Schraven, R. Martin, S. Ansorge, S. Brocke & D. Reinhold: TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J Immunol, 178, 4632-40 (2007)
36. Thielitz, A., D. Reinhold, R. Vetter, U. Bank, M. Helmuth, R. Hartig, S. Wrenger, I. Wiswedel, U. Lendeckel, T. Kahne, K. Neubert, J. Faust, C. C. Zouboulis, S. Ansorge & H. Gollnick: Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation. J Invest Dermatol, 127, 1042-51 (2007) (Pubitemid 46625127)
37. Geier, M. S., D. Tenikoff, R. Yazbeck, G. W. McCaughan, C. A. Abbott & G. S. Howarth: Development and resolutionof experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. J Cell Physiol, 204, 687-92 (2005) (Pubitemid 40934665)
38. Pospisilik, J. A., J. Martin, T. Doty, J. A. Ehses, N. Pamir, F. C. Lynn, S. Piteau, H. U. Demuth, C. H. McIntosh & R. A. Pederson: Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes, 52, 741-50 (2003) (Pubitemid 36323582)
39. Murthy, S. N., H. S. Cooper, H. Shim, R. S. Shah, S. A. Ibrahim & D. J. Sedergran: Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci, 38, 1722-34 (1993) (Pubitemid 23271431)
40. Howarth, G. S., C. J. Xian & L. C. Read: Predisposition to colonic dysplasia is unaffected by continuous administration of insulin-like growth factor-I for twenty weeks in a rat model of chronic inflammatory bowel disease. Growth Factors, 18, 119-33 (2000)
41. Gaudio, E., G. Taddei, A. Vetuschi, R. Sferra, G. Frieri, G. Ricciardi & R. Caprilli: Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects. Dig Dis Sci, 44, 1458-75 (1999) (Pubitemid 29404313)
42. Drucker, D. J.: Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol, 17, 161-71 (2003) (Pubitemid 36183142)
43. Abbott, C. A., R. Yazbeck, M. S. Geier, H. U. Demuth & G. S. Howarth: Dipeptidyl peptidases and inflammatory bowel disease. Adv Exp Med Biol, 575, 155-62 (2006)
44. Bank, U., A. Heimburg, M. Helmuth, S. Stefin, U. Lendeckel, D. Reinhold, J. Faust, P. Fuchs, B. Sens, K. Neubert, M. Tager & S. Ansorge: Triggering endogenous immunosuppressive mechanisms by combined targeting of Dipeptidyl peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/ CD13)-a novel approach for the treatment of inflammatory bowel disease. Int Immunopharmacol, 6, 1925-34 (2006) (Pubitemid 44855708)
45. Pauly, R. P., H. U. Demuth, F. Rosche, J. Schmidt, H. A. White, F. Lynn, C. H. McIntosh & R. A. Pederson:Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism, 48, 385-9 (1999) (Pubitemid 29116004)
46. Lankas, G. R., B. Leiting, R. S. Roy, G. J. Eiermann, M. G. Beconi, T. Biftu, C. C. Chan, S. Edmondson, W. P. Feeney, H. He, D. E. Ippolito, D. Kim, K. A. Lyons, H. O. Ok, R. A. Patel, A. N. Petrov, K. A. Pryor, X. Qian, L. Reigle, A. Woods, J. K. Wu, D. Zaller, X. Zhang, L. Zhu, A. E. Weber & N. A. Thornberry: Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes, 54, 2988-94 (2005) (Pubitemid 41401097)
47. Frerker, N., L. Wagner, R. Wolf, U. Heiser, T. Hoffmann, J. U. Rahfeld, J. Schade, T. Karl, H. Y. Naim, M. Alfalah, H. U. Demuth & S. von Horsten: Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4. Peptides, 28, 257-68 (2007) (Pubitemid 46188365)
48. Drucker, D. J., Q. Shi, A. Crivici, M. Sumner-Smith, W. Tavares, M. Hill, L. DeForest, S. Cooper & P. L. Brubaker: Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol, 15, 673-7 (1997) (Pubitemid 27291170)
49. Yazbeck, R., G. S. Howarth, H. U. Demuth, J. J. Holst & C. A. Abbott: Inhibition of dipeptidyl peptidase activity increases circulating glucagon-like peptide-2 and decreases neutrophil infiltration during experimental colitis in mice. Gastroenterology, 132, A369-A370 (2007)
50. Reinhold, D., U. Bank, F. Buhling, U. Lendeckel, J. Faust, K. Neubert & S. Ansorge: Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology, 91, 354-60 (1997) (Pubitemid 27304270)
51. Reinhold, D., B. Hemmer, B. Gran, I. Born, J. Faust, K. Neubert, H. F. McFarland, R. Martin & S. Ansorge: Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones. J Neuroimmunol, 87, 203-9 (1998) (Pubitemid 28319863)
52. Reinhold, D., U. Bank, F. Buhling, T. Kahne, D. Kunt, J. Faust, K. Neubert & S. Ansorge: Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells. Immunobiology, 192, 121-36 (1994)
53. Egger, B., M. Bajaj-Elliott, T. T. MacDonald, R. Inglin, V. E. Eysselein & M. W. Buchler: Characterisation of acutemurine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion, 62, 240-8 (2000)
54. Conarello, S. L., Z. Li, J. Ronan, R. S. Roy, L. Zhu, G. Jiang, F. Liu, J. Woods, E. Zycband, D. E. Moller, N. A. Thornberry & B. B. Zhang: Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci U S A, 100, 6825-30 (2003) (Pubitemid 36666664)